12 completed, 6 recruiting, 2 active not recruiting, 2 not yet recruiting. 8 Phase 2, 8 Phase 3, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 8 | Recruiting 5, Completed 2, Active not recruiting 1 |
| Phase 3 | 8 | Completed 4, Not yet recruiting 2, Active not recruiting 1, Recruiting 1 |
| Phase 1 | 6 | Completed 6 |
Follow TAK-279: new trials by email Literature Review of TAK-279 trials Research Report on TAK-279
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Zasocitinib in Adults With Psoriatic Arthritis (LATITUDE PsA NeXt) Placebo, Zasocitinib - Psoriatic Arthritis | Phase 3 | Not yet recruiting | Takeda | 644 | 2027-01-11 | 2026-10-13 |
| A Study of Zasocitinib in Adults With Non-pustular Palmoplantar Psoriasis Zasocitinib - Palmoplantar Psoriasis | Phase 3 | Not yet recruiting | Takeda | 40 | 2026-11-01 | 2026-10-20 |
| A Study of Zasocitinib (TAK-279) in Adults With Active Crohn's Disease Zasocitinib - Crohn's Disease | Phase 2 | Recruiting | Takeda | 20 | 2026-08-13 | 2026-08-24 |
| A Study of Zasocitinib in Adults With Hidradenitis Suppurativa Zasocitinib (Dose A), Placebo - Hidradenitis Suppurativa | Phase 2 | Recruiting | Takeda | 90 | 2026-01-26 | 2026-03-06 |
| A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis Zasocitinib, Placebo - Plaque Psoriasis | Phase 3 | Recruiting | Takeda | 110 | 2025-12-04 | 2026-09-09 |
| A Study of Zasocitinib in Adults With Nonsegmental Vitiligo Zasocitinib, Placebo - Nonsegmental Vitiligo | Phase 2 | Recruiting | Takeda | 200 | 2025-11-03 | 2026-09-30 |
| A Study Comparing Zasocitinib (TAK-279) With Deucravacitinib in Adults With Plaque Psoriasis Zasocitinib, Deucravacitinib, Placebo to match zasocitinib - Plaque Psoriasis | Phase 3 | Completed | Takeda | 606 | 2025-07-09 | 2026-05-01 |
| A Continuation Study of TAK-279 in Adults With Ulcerative Colitis (UC) and Crohn's Disease (CD) Zasocitinib - Crohn's Disease, Ulcerative Colitis | Phase 2 | Recruiting | Takeda | 192 | 2025-05-28 | 2026-05-22 |
| A Study of TAK-279 in Participants With Moderate-to-Severe Plaque Psoriasis TAK-279 - Plaque Psoriasis | Phase 3 | Active not recruiting | Takeda | 2099 | 2024-09-04 | 2026-06-02 |
| A Study of TAK-279 in Healthy Chinese Adults TAK-279, Placebo - Healthy Volunteers | Phase 1 | Completed | Takeda | 24 | 2024-06-24 | 2024-08-07 |
| A Study of TAK-279 in Healthy Adults on the Effect on ECG Measurements TAK-279, TAK-279 Placebo, Moxifloxacin - Healthy Volunteers | Phase 1 | Completed | Takeda | 120 | 2024-04-29 | 2024-07-11 |
| A Study of the Interaction of Other Drugs With TAK-279 in Healthy Adults Midazolam, Repaglinide, TAK-279 - Healthy Volunteers | Phase 1 | Completed | Takeda | 20 | 2024-03-29 | 2024-05-23 |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Ulcerative Colitis TAK-279, Placebo - Ulcerative Colitis | Phase 2 | Active not recruiting | Takeda | 213 | 2024-03-29 | 2026-08-17 |
| A Study of TAK-279 in Adult Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis TAK-279 - Generalized Pustular Psoriasis, Erythrodermic Psoriasis | Phase 3 | Completed | Takeda | 18 | 2024-03-19 | 2026-07-30 |
| A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease TAK-279, Placebo - Crohn's Disease | Phase 2 | Recruiting | Takeda | 268 | 2024-03-05 | 2026-09-25 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 52 Weeks of Treatment TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 693 | 2023-11-06 | 2025-10-24 |
| A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period TAK-279, Placebo, Apremilast - Plaque Psoriasis | Phase 3 | Completed | Takeda | 1108 | 2023-11-06 | 2025-11-20 |
| A Study of TAK-279 in Adults With or Without Kidney Problems TAK-279 - Renal Impairment, Healthy Volunteers | Phase 1 | Completed | Takeda | 24 | 2023-09-27 | 2024-06-27 |
| A Study of TAK-279 in Adults With or Without Liver Damage TAK-279 - Hepatic Impairment, Healthy Volunteers | Phase 1 | Completed | Takeda | 27 | 2023-09-22 | 2024-08-29 |
| A Study of the Interaction of TAK-279 With Substances That Have an Impact on Metabolism in Healthy Adults TAK-279, Erythromycin, Phenytoin - Healthy Volunteers | Phase 1 | Completed | Takeda | 172 | 2023-08-11 | 2024-02-06 |
Showing 20 of 22. Sign in to see all of them.
Crohn Disease (3) · Arthritis, Psoriatic (2) · Colitis, Ulcerative (2) · Psoriasis (2) · Hidradenitis Suppurativa (1) · Renal Insufficiency (1)
Takeda (22)
United States (17) · Poland (11) · China (10) · Canada (9) · Germany (8) · Japan (8) · Czechia (7) · France (7) · Italy (6) · Australia (5) · Bulgaria (5) · Hungary (5) · South Korea (5) · United Kingdom (5) · Israel (4)
PMID 39167366, PMID 42143206, PMID 42740479
2023 (4), 2025 (3)